NovoCure Limited (NVCR) Return on equity 2017–2026
NovoCure Limited (NVCR) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-40.0%FY2026 · since FY2017: -92.6% → -40.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -40.0% | +6.9 pp |
| FY2025 | -46.9% | +10.2 pp |
| FY2024 | -57.1% | -36.0 pp |
| FY2023 | -21.1% | -7.0 pp |
| FY2022 | -14.1% | -18.3 pp |
| FY2021 | 4.2% | +7.5 pp |
| FY2020 | -3.3% | +53.3 pp |
| FY2019 | -56.6% | -2.3 pp |
| FY2018 | -54.3% | +38.3 pp |
| FY2017 | -92.6% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice